A novel bioresorbable stent failed to meet the threshold for noninferiority compared with durable devices in the OPTIMIZE trial, and researchers suggested rising troponin use may have played a role.

NEW PROVIDENCE, N.J.--(BUSINESS WIRE)--Svelte® Medical Systems today announced completion of primary endpoint 6-month follow-up in DIRECT II (Direct Implantation of Rapamycin-Eluting stents with ...

Svelte® Medical Systems announced today it received conditional approval from the FDA to begin a pivotal study for the Svelte coronary stent Integrated Delivery System (IDS). Approved by the FDA under ...

(UPDATED) A low-profile, fixed-wire DES for direct stenting failed to meet a prespecified noninferiority composite endpoint of target lesion failure at 1 year against contemporary DES comparators, the ...

NEW PROVIDENCE, N.J.--Svelte® Medical Systems today announced enrollment of the final patient in the DIRECT II (Direct Implantation of Rapamycin-Eluting stents with bioabsorbable drug Carrier ...

Two coronary stent companies with very different treatment focuses heralded promising clinical advances in conjunction with the Transcatheter Cardiovascular Therapeutics conference in Miami on Oct. 22 ...

Percutaneous coronary intervention (PCI) in small coronary arteries continues to be a problem because it is usually associated with an increased risk of restenosis. [1] After either balloon ...

DIRECT RX Combines a New Class of Bioresorbable Drug Coating, Highly Conformable Stent Design and Proprietary Balloon Technology to Provide a Workhorse Coronary Drug-Eluting Stent (DES) Rapid-Exchange ...

NEW PROVIDENCE, N.J.--(BUSINESS WIRE)--Svelte® Medical Systems today announced the start of the FAASTER (First Assessment of the Acrobat Stenting Technique European Post-Market Registry) study in ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. HINSDALE, Ill. — Smaller, sleeker, faster.

New Providence, NJ's Svelte Medical announced the European launch of the Slender IDS drug-eluting stent, claiming it is the lowest profile device of its kind, resulting in smaller delivery catheter ...

NEW PROVIDENCE, N.J.--(BUSINESS WIRE)--Svelte® Medical Systems today announced enrollment of the final patient in the DIRECT II (Direct Implantation of Rapamycin-Eluting stents with bioabsorbable drug ...